DalsnaFinance Account

Teladoc Health Inc $TDOC

Health Care

Russell 2000 New York

Create a scorecard

$6.16

+0.42 (+7.42%)

As of Oct 20, 2026, 4:10 PM EDT · cached

Price history

Loading chart…

Teladoc Health Inc (TDOC) is trading up at $6.16 (+7.42%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: July 1, 2015 · $19.00 offering · New York Stock Exchange · View IPO details →

Teladoc Health Inc revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Teladoc Health Inc annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$123.2M	$233.3M	$417.9M	$553.3M	$1.09B	$2.03B	$2.41B	$2.60B	$2.57B	$2.53B
Growth (year over year)	+59.2%	+89.4%	+79.1%	+32.4%	+97.7%	+85.8%	+18.4%	+8.1%	−1.3%	−1.5%
Gross profit	$91.2M	$171.7M	$289.2M	$368.8M	$703.1M	$1.38B	$1.66B	$1.84B	$1.82B	$1.76B
Gross margin	74.0%	73.6%	69.2%	66.7%	64.3%	68.0%	69.1%	70.8%	70.8%	69.5%
Operating income	−$62.7M	−$75.4M	−$70.9M	−$80.4M	−$506.4M	−$265.6M	−$13.7B	−$248.6M	−$1.02B	−$263.0M
Operating margin	−50.9%	−32.3%	−17.0%	−14.5%	−46.3%	−13.1%	−567.3%	−9.6%	−39.7%	−10.4%
Net income	−$74.2M	−$106.8M	−$97.1M	−$98.9M	−$485.1M	−$428.8M	−$13.7B	−$220.4M	−$1.00B	−$200.3M
Net margin	−60.3%	−45.8%	−23.2%	−17.9%	−44.3%	−21.1%	−567.5%	−8.5%	−39.0%	−7.9%
EPS (diluted)	−$1.75	−$1.93	−$1.47	−$1.38	−$5.36	−$2.73	−$84.60	−$1.34	−$5.87	−$1.14
Balance sheet
Cash and equivalents	$50.0M	$42.8M	$424.0M	$514.4M	$733.3M	$893.5M	$918.2M	$1.12B	$1.30B	$781.1M
Total assets	$303.7M	$824.4M	$1.53B	$1.60B	$17.8B	$17.7B	$4.35B	$4.39B	$3.52B	$2.86B
Total liabilities	$72.8M	$265.5M	$515.8M	$588.8M	$1.87B	$1.69B	$2.04B	$2.07B	$2.03B	$1.47B
Long-term debt	$42.4M	—	—	—	—	—	—	—	—	—
Shareholders' equity	$230.9M	$558.9M	$1.01B	$1.01B	$15.9B	$16.0B	$2.31B	$2.33B	$1.49B	$1.39B
Cash flow
Operating cash flow	−$51.9M	−$34.4M	−$4.86M	$29.9M	−$53.5M	$194.0M	$189.3M	$350.0M	$293.7M	$294.4M
Capital expenditure	$2.11M	$2.63M	$4.01M	$3.51M	$4.02M	$8.53M	$16.5M	$11.5M	$10.8M	$8.89M
Free cash flow	−$54.0M	−$37.1M	−$8.87M	$26.4M	−$57.5M	$185.5M	$172.8M	$338.6M	$282.9M	$285.5M

RevenueNet incomeNet margin (right axis, %)

Teladoc Health Inc quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$640.5M	$640.5M	$629.4M	$631.9M	$626.4M	$642.3M	$613.8M	$606.9M
Growth (year over year)	−3.0%	−3.0%	−2.6%	−1.6%	−2.2%	+0.3%	−2.5%	−4.0%
Gross profit	$460.8M	$451.6M	$432.5M	$441.4M	$439.3M	$445.2M	$416.3M	$416.1M
Gross margin	71.9%	70.5%	68.7%	69.8%	70.1%	69.3%	67.8%	68.6%
Operating income	−$44.4M	−$48.2M	−$120.6M	−$54.4M	−$52.0M	−$36.0M	−$61.8M	−$37.1M
Operating margin	−6.9%	−7.5%	−19.2%	−8.6%	−8.3%	−5.6%	−10.1%	−6.1%
Net income	−$33.3M	−$48.4M	−$93.0M	−$32.7M	−$49.5M	−$25.1M	−$63.8M	−$38.9M
Net margin	−5.2%	−7.6%	−14.8%	−5.2%	−7.9%	−3.9%	−10.4%	−6.4%
EPS (diluted)	−$0.19	−$0.27	−$0.53	−$0.19	−$0.28	−$0.14	−$0.36	−$0.21
Balance sheet
Cash and equivalents	$1.24B	$1.30B	$1.19B	$679.6M	$726.2M	$781.1M	$750.7M	$774.3M
Total assets	$3.53B	$3.52B	$3.44B	$2.89B	$2.88B	$2.86B	$2.81B	$2.76B
Total liabilities	$2.02B	$2.03B	$2.02B	$1.47B	$1.49B	$1.47B	$1.47B	$1.45B
Shareholders' equity	$1.51B	$1.49B	$1.43B	$1.42B	$1.39B	$1.39B	$1.34B	$1.31B
Cash flow
Operating cash flow	$110.2M	$85.9M	$15.9M	$91.4M	$99.3M	$87.7M	$9.52M	$64.7M
Capital expenditure	$1.60M	$6.13M	$2.73M	$1.27M	$2.28M	$2.62M	$1.66M	$928.0K
Free cash flow	$108.6M	$79.8M	$13.2M	$90.2M	$97.0M	$85.1M	$7.86M	$63.7M

From Teladoc Health Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →